A variety of evidence implicates IL-6 in the pathogenesis of depression [9, 29, 30], and a phase 2 trial of sirukumab for patients with MDD and CRP >3 mg/L has recently completed (clinicaltrials.gov ID: NCT02473289). This evidence concerns the gene IL6 and depressive disorder.